MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism
about
CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycleCircumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsApoptosis induction by MEK inhibition in human lung cancer cells is mediated by BimA mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.Bim protein degradation contributes to cisplatin resistance.Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaRhein lysinate inhibits cell growth by modulating various mitogen-activated protein kinases in cervical cancer cells.Caspase-9 mediates Puma activation in UCN-01-induced apoptosis.Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cellsSynergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.Environmental-mediated drug resistance: a target for multiple myeloma therapy.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.Enhancing CHK1 inhibitor lethality in glioblastoma.ATR/CHK1 inhibitors and cancer therapy.Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression.
P2860
Q24622357-3C8CE6BF-5E6C-4B3B-BA9E-C8BB67D80AB5Q28540339-FB79756C-48B5-443C-8AD1-0BA6E2AA55B7Q28749134-C44E3A83-DD92-40B3-A30B-DF19C9AA2FA8Q30498959-65F8AB77-6551-489F-B357-BED62CC87512Q33840360-35F4E9C3-2CA4-44EF-A79D-05F0D9D0BAABQ34017354-42CE18A2-F4C0-4BC7-AFFE-0637941BF605Q34300057-4BA1356D-C0CD-414D-8A8F-5A81F0599F47Q34667764-810404DF-63E4-41CB-A677-48079398EA44Q35063113-D6F84599-589D-4EED-B68B-7A75AF1DA53BQ36110746-074C60E4-1D0E-4B9B-B449-78D074A908D0Q36142370-E3B16596-176C-4FCF-8D5F-F72A0DA26177Q36291178-FB00DBC3-EB22-4F38-97DA-556254064BE9Q36868759-FF7CB7FF-23A2-4E84-8B87-07FEB4264895Q37227994-BB5D6337-A2C6-49DB-94B7-AF7E010CFFA0Q37451892-6D754C97-02CF-4441-B506-99711702D9CCQ37605160-88ABD398-1884-44BC-9FD7-6567DEC01C71Q37810085-8A79FF2B-CABF-46A5-8B8A-C3D33A321F04Q40063670-AF02A396-7CBD-48FE-8BD3-CEA41F24F871Q41767263-85247C79-D06B-4252-8D21-8BD5C1D064B2Q47622968-9945F92C-1DFD-4FFB-B52A-3C703F935B1FQ52619351-3275144D-939C-4D43-AAF8-428716824DC1
P2860
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
MEK1/2 inhibitors potentiate U ...... ough a Bim-dependent mechanism
@ast
MEK1/2 inhibitors potentiate U ...... ough a Bim-dependent mechanism
@en
type
label
MEK1/2 inhibitors potentiate U ...... ough a Bim-dependent mechanism
@ast
MEK1/2 inhibitors potentiate U ...... ough a Bim-dependent mechanism
@en
prefLabel
MEK1/2 inhibitors potentiate U ...... ough a Bim-dependent mechanism
@ast
MEK1/2 inhibitors potentiate U ...... ough a Bim-dependent mechanism
@en
P2093
P2860
P1433
P1476
MEK1/2 inhibitors potentiate U ...... ough a Bim-dependent mechanism
@en
P2093
Hisashi Harada
Jianghua Lu
Sarah Tenorio
Steven Grant
Xin-Yan Pei
P2860
P304
P356
10.1182/BLOOD-2007-04-083204
P407
P50
P577
2007-05-31T00:00:00Z